US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

SpyGlass Pharma (SGP): Six Months Later: Strong Debut Holds Above Water as Investors Await Data

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Channel checks indicate SpyGlass Pharma’s IPO is oversubscribed at launch, with interest from both new investors and existing shareholders.</li>
<li>Lead BIM-IOL System combines cataract surgery with long-acting drug delivery, addressing glaucoma adherence challenges through a streamlined, surgeon-friendly approach.</li>
<li>Backed by top-tier investors and advancing Phase 3 trials, SpyGlass presents a late-stage, differentiated healthcare IPO setup.</li>
</ul>


Channel checks indicate SpyGlass Pharma’s IPO is oversubscribed at launch, with interest from both new investors and existing shareholders.
Lead BIM-IOL System combines cataract surgery with long-acting drug delivery, addressing glaucoma adherence challenges through a streamlined, surgeon-friendly approach.
Backed by top-tier investors and advancing Phase 3 trials, SpyGlass presents a late-stage, differentiated healthcare IPO setup.


SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction